CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
巨细胞病毒特异性免疫治疗用于胶质母细胞瘤治疗
英文原题：Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments.
查看英文原题
Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去二十年中，大量研究调查了胶质母细胞瘤或胶质瘤中人巨细胞病毒（CMV）的存在情况；然而，结果严重矛盾。虽然少数研究者提出细胞毒性T淋巴细胞或树突状细胞疫苗对复发或新诊断胶质母细胞瘤患者可能有益，但多项研究完全不同意胶质母细胞瘤细胞中存在CMV。在本综述中，我们总结了关于胶质母细胞瘤或胶质瘤患者中CMV检测的矛盾结果和问题。我们还提供了已发表和未发表的针对胶质母细胞瘤使用CMV特异性免疫治疗的临床试验的临床数据。
展开英文摘要原文
Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting.
While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients.
We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.
论文信息
- 作者
- Ahn J、Shin C、Kim YS、Park JS、Jeun SS、Ahn S
- 第一作者单位
- College of Medicine, The Catholic University of Korea, Seoul, Korea.South Korea
- 通讯作者单位
- Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. nsstp@catholic.ac.kr.South Korea
- 文献类型
- 综述
- 期刊
- Brain tumor research and treatment2022 Jul
- 原文标识
- PubMed 35929110 · DOI 10.14791/btrt.2022.0010
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →